Recently, the “China Equity Investment Annual Summit and 2016 Investor Network Annual Meeting†was held in Beijing. With the theme of “Capital Opportunities in Changeâ€, the industry and industry veterans were invited to discuss key elements of the integration of industry and finance and investment in the new era. Hot topics such as the pattern and growth trends of various industries. At the summit, Investor Network and the China Science and Technology Finance Promotion Association Venture Capital Professional Committee issued the "China Equity Investment Annual Series List".
Share investment management partner Huang and others expressed their views on the future medical and medical health big data industry in the “ Medical Health Specialâ€. In his view, in the past few decades, humans have spent hundreds of billions of dollars and billions of dollars each year to study oncology drugs, but these tumor drugs are not so obvious for human tumors or life. The emergence of precision medicine enables humans to have a very in-depth and accurate understanding of the causative factors, so that personalized and accurate medical solutions can be adopted to achieve better therapeutic effects.
Huang said that precision medicine is not only a hot topic in the past one or two years, but also the era of precision medicine. And big data will determine how far future precision medicine can go. "The medical and biological big data we produce every day is a huge amount of things. If no one turns it into a visualization and can't provide it to doctors, R&D institutions become available products, it produces garbage every year."
Yellow
Regarding the investment opportunities for medical big data , Huang said that it will be reflected in six aspects. First, early screening diagnosis; second, early warning of serious illness; third, machine learning/laboratory reading; fourth, self-diagnosis; fifth, insurance control fee; sixth, efficacy evaluation.
The following is a wonderful speech by Huang and vice versa at the "China Equity Investment Annual Summit and 2016 Investor Network Annual Meeting".
Investment logic for medical health big data
Hello everyone, I am very happy to share with you at the Annual Network of Investment Network. The topic I chose today is “Investment Logic of Medical Health Big Data.†Why did you choose this topic? Because sharing investment is a VC agency, VC is always looking to the future.
Ma Yun said that the richest man in the future will definitely appear in the field of medical health, and he said that it has now entered the DT era from the IT era. Both of these points represent the future direction, so today we will combine these two points to talk about the future of medical care.
First of all, what is called future medical care, you may still have to talk about precision medicine first. Precision medicine is a very hot topic in the past two years. Our focus today is to compare why the future is the era of precision medicine.
In the past few decades, it has been the era of evidence-based medicine. Evidence-based medicine is considered to represent the development of science in comparison with the experience medicine we said decades ago. It has made great progress compared with Chinese medicine. But there are some problems with evidence-based medicine, and many problems are insurmountable. For example, evidence-based medicine is based on the location and symptoms of the disease, combined with some testing methods, including some imaging, pathology, and test data to assist doctors in judging the disease and giving treatment options.
But what we have seen, unfortunately, many people have the same condition in the same part, and the same treatment plan, but the effect is very different. Humans spend hundreds of billions of dollars and trillions of dollars to study oncology drugs, but these tumor drugs are not so obvious for the improvement of human tumors or life. On average, the life extension of patients is between 2-3 months.
Why has evidence-based medicine developed for so many years and faced such a big problem? In fact, it is problematic to judge and treat this part and symptoms. The problem is that he did not find out what the true pathogenic factor of the disease is. So everyone took the same plan, but because each person has different virulence factors, the effect is very different.
If you are the lucky one, you have been treated with this medicine 100%. If it is not for this virulence factor, the end result is a lot of money was wasted and life cannot be saved.
Powder For Injection,Benzylpenicillin Potassium For Injection,Ceftiofur Sodium For Injection,Poultry Medication
Sichuan Aibang Weiye Biological Engineering Co., Ltd. , https://www.aibangpharm.com